Amicus Therapeutics, Inc. (NASDAQ:FOLD)‘s stock had its “outperform” rating reissued by investment analysts at Cowen and Company in a report issued on Thursday. They presently have a $18.00 price objective on the biopharmaceutical company’s stock, up from their prior price objective of $16.00. Cowen and Company’s price target points to a potential upside of 33.33% from the company’s previous close.

Other research analysts have also recently issued reports about the stock. J P Morgan Chase & Co set a $13.00 price target on shares of Amicus Therapeutics and gave the company a “buy” rating in a research report on Monday, June 5th. Chardan Capital restated a “buy” rating and set a $12.50 price objective on shares of Amicus Therapeutics in a research note on Thursday, June 1st. Bank of America Corporation reduced their price objective on shares of Amicus Therapeutics from $10.00 to $9.00 and set a “buy” rating for the company in a research note on Thursday, May 25th. BidaskClub upgraded shares of Amicus Therapeutics from a “hold” rating to a “buy” rating in a research note on Friday, June 16th. Finally, ValuEngine upgraded shares of Amicus Therapeutics from a “sell” rating to a “hold” rating in a research note on Friday, June 9th. Two analysts have rated the stock with a hold rating and seven have given a buy rating to the company’s stock. The company presently has a consensus rating of “Buy” and an average target price of $14.75.

Shares of Amicus Therapeutics (FOLD) traded down 1.26% during midday trading on Thursday, reaching $13.35. 1,787,126 shares of the company’s stock were exchanged. The stock’s market capitalization is $2.20 billion. Amicus Therapeutics has a 12-month low of $4.41 and a 12-month high of $14.36. The firm has a 50-day moving average of $13.20 and a 200-day moving average of $9.66.

Amicus Therapeutics (NASDAQ:FOLD) last issued its quarterly earnings results on Monday, August 7th. The biopharmaceutical company reported ($0.34) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.37) by $0.03. Amicus Therapeutics had a negative net margin of 1,279.88% and a negative return on equity of 61.25%. The company had revenue of $7.16 million during the quarter, compared to analysts’ expectations of $6.96 million. During the same period last year, the company posted ($0.40) EPS. Analysts anticipate that Amicus Therapeutics will post ($1.37) EPS for the current fiscal year.

COPYRIGHT VIOLATION NOTICE: “Cowen and Company Reiterates “Outperform” Rating for Amicus Therapeutics, Inc. (FOLD)” was posted by American Banking News and is owned by of American Banking News. If you are viewing this article on another site, it was copied illegally and republished in violation of US & international trademark and copyright law. The correct version of this article can be viewed at https://www.americanbankingnews.com/2017/09/14/cowen-and-company-reiterates-outperform-rating-for-amicus-therapeutics-inc-fold.html.

In other Amicus Therapeutics news, insider Jay Barth sold 30,000 shares of Amicus Therapeutics stock in a transaction that occurred on Monday, June 19th. The shares were sold at an average price of $10.00, for a total transaction of $300,000.00. Following the transaction, the insider now owns 64,184 shares of the company’s stock, valued at $641,840. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. Also, major shareholder Life Sciences Maste Perceptive purchased 1,500,000 shares of the stock in a transaction on Thursday, July 13th. The shares were purchased at an average cost of $12.25 per share, for a total transaction of $18,375,000.00. The disclosure for this purchase can be found here. Insiders own 3.40% of the company’s stock.

A number of large investors have recently modified their holdings of the business. Bank of Nova Scotia purchased a new position in Amicus Therapeutics during the second quarter valued at approximately $1,944,000. Redmile Group LLC lifted its holdings in Amicus Therapeutics by 5.9% during the second quarter. Redmile Group LLC now owns 12,043,932 shares of the biopharmaceutical company’s stock valued at $121,282,000 after purchasing an additional 668,080 shares in the last quarter. State Street Corp lifted its holdings in Amicus Therapeutics by 2.2% during the second quarter. State Street Corp now owns 5,892,564 shares of the biopharmaceutical company’s stock valued at $59,332,000 after purchasing an additional 125,635 shares in the last quarter. Gotham Asset Management LLC purchased a new position in Amicus Therapeutics during the second quarter valued at approximately $308,000. Finally, Palo Alto Investors LLC lifted its holdings in Amicus Therapeutics by 0.7% during the second quarter. Palo Alto Investors LLC now owns 7,940,788 shares of the biopharmaceutical company’s stock valued at $79,964,000 after purchasing an additional 57,800 shares in the last quarter.

About Amicus Therapeutics

Amicus Therapeutics, Inc is a biotechnology company. The Company is engaged in the discovery, development and commercialization of a set of treatments for patients living with devastating rare and orphan diseases. Its lead product, migalastat HCl is a small molecule that can be used as a monotherapy and in combination with enzyme replacement therapy (ERT) for Fabry disease.

Analyst Recommendations for Amicus Therapeutics (NASDAQ:FOLD)

Receive News & Ratings for Amicus Therapeutics Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Amicus Therapeutics Inc. and related companies with MarketBeat.com's FREE daily email newsletter.